# ::id 1
# ::snt A new cancer drug proved strikingly successful with very few side effects in treating a relatively rare form of leukemia, researchers said
(x23 / say-01
	:ARG1 (x7 / succeed-01
		:ARG1 (x4 / drug
			:mod (x2 / new)
			:mod (x3 / cancer))
		:mod (x6 / strikingly)
		:ARG1 (x12 / effect
			:quant (x10 / few
				:degree (x9 / very))
			:mod (x11 / side))
		:ARG2 (x14 / treat-02
			:ARG1 (x18 / form
				:mod (x17 / rare
					:degree (x16 / relative))
				:mod (x20 / disease
					:name (n / name
						:op1 "leukemia")))))
	:ARG0 (x22 / person
		:ARG0-of (r / research-01)))

# ::id 2
# ::snt The drug, called 2-CdA, was nearly 100 % effective treating 12 patients with hairy-cell leukemia
(x11 / effective
	:domain (x2 / drug
		:ARG1-of (x4 / call-01))
	:duration (x8 / nearly)
	:domain (x12 / treat-02
		:ARG1 (x14 / patient
			:quant 12)
		:ARG2 (x17 / disease
			:name (n / name
				:op1 "leukemia")
			:mod (x16 / hairy-cell))))

# ::id 3
# ::snt The patients underwent just one seven-day treatment and experienced almost none of the debilitating side effects such as vomiting, hair-loss and kidney and liver problems associated with other chemotherapy
(x3 / undergo-01
	:ARG1 (x2 / patient)
	:ARG1 (x7 / treat-03
		:quant (x4 / just
			:op1 1)
		:duration (x6 / person
			:name (n / name
				:op1 "seven-day")))
	:null_edge (x8 / and
		:op2 (x9 / experience-01
			:ARG0 x2
			:ARG1 (x16 / effect
				:mod (x11 / none
					:degree (x10 / almost))
				:mod (x14 / debilitating)
				:mod (x15 / side)
				:example (x22 / and
					:op1 (x19 / vomiting)
					:op2 (x21 / hair-loss)
					:op2 (x24 / and
						:op1 (x23 / kidney)
						:op2 (x25 / liver)
						:op2 (x26 / problem
							:ARG1-of (x27 / associate-01
								:ARG2 (x30 / chemotherapy
									:mod (x29 / other))))))))))

# ::id 4
# ::snt The results need to be replicated by other researchers before definitive conclusions can be made, and the long-term effect of the treatment remains unknown
(x3 / need-01
	:ARG0 (x2 / thing
		:ARG2-of (r / result-01))
	:ARG1 (x6 / replicate-01
		:ARG1 x2
		:ARG0 (x9 / person
			:ARG0-of (r1 / research-01)
			:mod (x8 / other))
		:time (x10 / before
			:op1 (x13 / possible
				:domain (x15 / make-01
					:ARG1 (x12 / thing
						:ARG1-of (c / conclude-01)
						:mod (x11 / definitive))))))
	:ARG1 (x24 / remain-01
		:ARG1 (x17 / and)
		:ARG1 (x20 / effect-01
			:duration (x19 / long)
			:ARG0 (x23 / treat-03))
		:ARG3 (x25 / know-01
			:polarity -)))

# ::id 5
# ::snt But the initial experience with the compound is especially promising, and an apparent improvement over other therapy for the disease, scientists said
(x24 / say-01
	:ARG1 (x12 / and
		:op1 (x10 / promising
			:null_edge (x1 / contrast-01)
			:domain (x4 / experience
				:mod (x3 / initial)
				:ARG1 (x7 / compound-01))
			:mod (x9 / especially))
		:op2 (x15 / improve-01
			:manner (x14 / apparency)
			:ARG1 (x18 / therapy
				:mod (x17 / other)
				:beneficiary (x21 / disease))))
	:ARG0 (x23 / scientist))

# ::id 6
# ::snt " There are n't many -LCB- drugs -RCB- where you can administer one course of treatment and have the disease go away and stay away for as long as four years, " says Lawrence Piro, chief of cancer research at Scripps Clinic & Research Foundation, La Jolla, Calif., where the drug was developed
(x34 / say-01
	:ARG1 (x5 / many)
	:ARG1 (x11 / possible
		:domain (x12 / administer-01
			:ARG1 (x7 / drug)
			:ARG0 (x10 / you)
			:ARG1 (x17 / and
				:op1 (x16 / treat-03))
			:ARG1 (x23 / and
				:op1 (x21 / go-01
					:ARG1 (x20 / disease))
				:op2 (x24 / stay-01
					:direction (x25 / away)
					:duration (x31 / temporal-quantity
						:unit (y / year)
						:null_edge (x28 / long))))))
	:ARG0 (x35 / newspaper
		:name (n / name
			:op1 "Lawrence"
			:op2 "Piro")
		:ARG0-of (x38 / have-org-role-91
			:ARG2 (c / chief)
			:topic (x41 / research-01
				:ARG1 (x40 / cancer))
			:location (x43 / government-organization
				:name (n1 / name
					:op1 "Scripps"
					:op2 "Clinic"
					:op3 "&"
					:op4 "Research"
					:op5 "Foundation")
				:location (x50 / country
					:name (n2 / name
						:op1 "Jolla")
					:null_edge (x49 / country
						:name (n3 / name
							:op1 "La"))
					:null_edge (x52 / country
						:name (n4 / name
							:op1 "Calif.")))
				:ARG1-of (x58 / develop-02
					:ARG1 (x56 / drug))))))

# ::id 7
# ::snt " The leukemia has n't come back in any of the patients we treated .
(x6 / come-01
	:ARG1 (x3 / disease
		:name (n / name
			:op1 "leukemia"))
	:direction (x7 / back)
	:ARG2 (x12 / patient
		:mod (x9 / any)
		:ARG1-of (x14 / treat-01
			:ARG0 (x13 / we))))

# ::id 8
# ::snt The study is published in today's New England Journal of Medicine
(x4 / publish-01
	:ARG1 (x2 / study)
	:location (x10 / journal
		:time (x6 / today)
		:null_edge (x8 / null_tag)
		:poss (x9 / country
			:name (n / name
				:op1 "England"))
		:null_edge (x12 / medicine)))

# ::id 9
# ::snt " It is without doubt the most effective treatment for hairy-cell leukemia, in terms of rapidity of response, " adds Elihu H. Estey, a cancer researcher at the University of Texas-M.D. Anderson Cancer Center, Houston
(x22 / add-02
	:ARG1 (x9 / treat-03
		:manner (x5 / doubt-01)
		:mod (x8 / effective
			:degree (x7 / most))
		:ARG2 (x12 / disease
			:name (n1 / name
				:op1 "leukemia")
			:mod (x11 / hairy-cell))
		:ARG0 (x17 / rapidity
			:ARG2-of (x19 / respond-01)))
	:ARG0 (x23 / person
		:name (n / name
			:op1 "Elihu"
			:op2 "H."
			:op3 "Estey")
		:ARG0-of (x29 / research-01
			:ARG1 (x28 / cancer)
			:ARG1 (x32 / government-organization
				:name (n2 / name
					:op1 "University"
					:op2 "of"
					:op3 "Texas-M.D."
					:op4 "Anderson"
					:op5 "Cancer"
					:op6 "Center")
				:location (x39 / country
					:name (n3 / name
						:op1 "Houston"))))))

# ::id 10
# ::snt Dr. Estey recently began treating patients with 2-CdA and has had similar results with five patients
(x9 / and
	:op1 (x4 / begin-01
		:ARG0 (x2 / person
			:name (n / name
				:op1 "Estey"))
		:time (x3 / recent)
		:ARG1 (x5 / treat-02
			:ARG0 x2
			:ARG1 (x6 / patient))
		:ARG1 (x8 / 2-cda)
		:ARG1 (x13 / thing
			:ARG2-of (r / result-01)
			:ARG1-of (x12 / resemble-01
				:op (s / similar))
			:ARG2 (x16 / patient
				:quant 5))))

# ::id 11
# ::snt " It's a striking finding, " he says
(x10 / say-01
	:ARG1 (x6 / thing
		:ARG1-of (f / find-01)
		:mod (x5 / strike-01))
	:ARG0 (x9 / he))

# ::id 12
# ::snt " It's very unlikely to be a fluke .
(x5 / likely
	:polarity -
	:degree (x4 / very)
	:domain (x9 / fluke))

# ::id 13
# ::snt Hairy-cell leukemia, so-called because of the appearance of the cancerous cells under the microscope, affects about 6,000 people in the U.S., with 600 new cases a year
(x17 / affect-01
	:ARG0 (x2 / disease
		:name (n / name
			:op1 "leukemia")
		:mod (x1 / hairy-cell)
		:mod (x4 / so-called
			:ARG1-of (x5 / cause-01
				:ARG0 (x8 / appear-01
					:ARG1 (x12 / cell
						:mod (x11 / cancerous)
						:part-of (x15 / microscope))))))
	:ARG1 (x18 / about
		:op1 (x19 / 6,000))
	:ARG2 (x28 / case
		:location (x23 / country
			:name (n1 / name
				:op1 "U.S."))
		:quant 600
		:mod (x27 / new)))

# ::id 14
# ::snt As the disease progresses, patients become anemic, are vulnerable to infection and often need blood transfusions
(x7 / become-01
	:ARG2 (x4 / progress-01
		:ARG0 (x3 / disease))
	:ARG1 (x6 / patient)
	:ARG1 (x14 / and
		:op1 (x8 / anemic)
		:op2 (x11 / vulnerable
			:prep-to (x13 / infect-01))
		:op2 (x16 / need-01
			:ARG0 x6
			:frequency (x15 / often)
			:ARG1 (x18 / transfusion
				:mod (x17 / blood)))))

# ::id 15
# ::snt Until the mid-1980s, treatments were ineffective, and patients often died of blood problems and infections
(x9 / and
	:op1 (x7 / effective
		:polarity -
		:time (x1 / until
			:time (x3 / date-entity))
		:domain (x5 / treat-03))
	:op2 (x12 / die-01
		:ARG1 (x10 / patient)
		:frequency (x11 / often)
		:ARG1 (x16 / and
			:op1 (x15 / problem
				:mod (x14 / blood))
			:op2 (x17 / infect-01))))

# ::id 16
# ::snt Since then, alpha interferon, a drug sold by Hoffmann-La Roche Inc. and Schering-Plough Corp. and an experimental drug called deoxycoformycin have significantly reduced death rates from hairy-cell leukemia
(x25 / reduce-01
	:time (x1 / since
		:op1 (x2 / then))
	:ARG0 (x17 / and
		:op1 (x5 / interferon
			:mod (x4 / alpha))
		:op2 (x8 / drug
			:ARG1-of (x9 / sell-01
				:ARG0 (x14 / and
					:op1 (x11 / government-organization
						:name (n1 / name
							:op1 "Hoffmann-La"
							:op2 "Roche"
							:op3 "Inc."))
					:op2 (x16 / organization
						:name (n2 / name
							:op1 "Corp.")
						:null_edge (x15 / organization
							:name (n3 / name
								:op1 "Schering-Plough"))))))
		:op2 (x20 / drug
			:mod (x19 / experiment-01)
			:ARG1-of (x22 / deoxycoformycin)))
	:degree (x24 / significant)
	:ARG1 (x27 / rate
		:mod (x26 / die-01))
	:ARG2 (x30 / disease
		:name (n / name
			:op1 "leukemia")
		:mod (x29 / hairy-cell)))

# ::id 17
# ::snt Hoffmann-La Roche is the U.S. subsidiary of F. Hoffmann-La Roche & Co. of Switzerland
(x6 / subsidiary
	:domain (x1 / newspaper
		:name (n / name
			:op1 "Hoffmann-La"
			:op2 "Roche"))
	:mod (x5 / country
		:name (n1 / name
			:op1 "U.S."))
	:part-of (x8 / government-organization
		:name (n2 / name
			:op1 "F."
			:op2 "Hoffmann-La"
			:op3 "Roche"
			:op4 "&")
		:poss (x14 / country
			:name (n3 / name
				:op1 "Switzerland"))))

# ::id 18
# ::snt 
(x34 / say-01
	:ARG1 (x1 / contrast-01
		:ARG2 (x6 / effective
			:domain (x3 / drug))
		:ARG2 (x9 / appear-02
			:ARG1 (x8 / 2-cda)
			:ARG1 (x14 / dose
				:mod (x13 / low)))
		:ARG2 (x15 / and
			:op2 (x17 / possible
				:domain (x18 / cause-01
					:ARG0 (x16 / both)
					:ARG1 (x21 / effect-01
						:mod (x19 / such)
						:mod (x20 / side)
						:mod (x25 / thing
							:manner-of (v / vomit-02)
							:ARG1 (x29 / and
								:op1 (x23 / nausea)
								:op2 (x28 / rash
									:mod (x27 / skin))
								:op2 (x31 / disorder))))))))
	:ARG0 (x33 / person
		:ARG0-of (r / research-01)))

# ::id 19
# ::snt " With the lack of toxicity and the ease with which people go into remission -LCB- with 2-CdA -RCB-, I think there's something really going on here, " says Ellin Berman, a staff leukemia doctor at Memorial Sloan Kettering Cancer Center, New York
(x32 / say-01
	:ARG1 (x22 / think-01
		:ARG0 (x21 / i)
		:ARG1 (x27 / go-15
			:ARG1 (x25 / something)
			:null_edge (x26 / really)
			:location (x29 / here))
		:ARG0-of (xap0 / cause-01
			:ARG0 (x4 / lack-01
				:ARG1 (x6 / toxicity)
				:ARG1 (x7 / and
					:op2 (x9 / ease))
				:time (x13 / go-02
					:ARG4 (x15 / remission)
					:manner (x18 / 2-cda)))))
	:ARG0 (x33 / newspaper
		:name (n / name
			:op1 "Ellin"
			:op2 "Berman")
		:ARG0-of (x39 / doctor
			:consist-of (x37 / person
				:ARG2-of (s / staff-01))
			:mod (x38 / disease
				:name (n1 / name
					:op1 "leukemia"))
			:location (x41 / government-organization
				:name (n2 / name
					:op1 "Memorial"
					:op2 "Sloan"
					:op3 "Kettering"
					:op4 "Cancer"
					:op5 "Center")
				:location (x48 / country
					:name (n3 / name
						:op1 "York")
					:null_edge (x47 / null_tag))))))

# ::id 20
# ::snt Scripps said it negotiated an agreement with a subsidiary of Johnson & Johnson, New Brunswick, N.J., to produce and distribute 2-CdA to other centers for broader clinical trials
(x2 / say-01
	:ARG0 (x1 / organization
		:name (n / name
			:op1 "Scripps"))
	:ARG1 (x4 / negotiate-01
		:ARG1 (x6 / agree-01
			:ARG1 (x9 / subsidiary
				:part-of (x11 / company
					:name (n1 / name
						:op1 "Johnson"
						:op2 "&"
						:op3 "Johnson")
					:location (x16 / country
						:name (n2 / name
							:op1 "Brunswick")
						:null_edge (x15 / null_tag)
						:null_edge (x18 / country
							:name (n3 / name
								:op1 "N.J.")))))
			:ARG1 (x22 / and
				:op1 (x21 / produce-01
					:ARG1 (x24 / 2-cda)
					:ARG2 (x27 / center
						:mod (x26 / other)
						:ARG2 (x31 / trial
							:mod (x29 / broad)
							:mod (x30 / clinic))))
				:op3 (x23 / distribute-01)))))

# ::id 21
# ::snt The researchers said the drug is easy to produce and thus is likely to be less expensive than other cancer treatments
(x3 / say-01
	:ARG0 (x2 / person
		:ARG0-of (r / research-01))
	:ARG1 (x10 / and
		:op2 (x7 / easy
			:domain (x5 / drug)
			:domain (x9 / produce-01))
		:op2 (x13 / likely
			:domain (x17 / expensive
				:degree (x16 / less)
				:domain (x21 / treat-03
					:mod (x19 / other)
					:mod (x20 / cancer))))))

# ::id 22
# ::snt In the 12-patient study, 2-CdA, short for 2-chlorodeoxyadenosine, was administered continuously for seven days to patients aged 36 to 61
(x13 / administer-01
	:part-of (x4 / study-01
		:mod (x3 / 12-patient))
	:ARG1 (x6 / 2-cda)
	:duration (x8 / short
		:ARG2 (x10 / 2-chlorodeoxyadenosine))
	:ARG1-of (x14 / continue-01)
	:duration (x17 / temporal-quantity
		:unit (d / day)
		:quant 7)
	:ARG2 (x19 / patient
		:ARG1-of (x20 / age-01
			:ARG1 36
			:ARG2 61)))

# ::id 23
# ::snt Within eight to 10 weeks, 11 of the patients had no trace of cancer in their blood or bone marrow ; the 12th had a small amount remaining in the marrow, but he declined further bone marrow monitoring, Dr. Piro said
(x44 / say-01
	:ARG1 (x34 / contrast-01
		:time (x1 / within
			:op1 (x5 / temporal-quantity
				:unit (w / week)
				:quant 10))
		:ARG2 (x10 / patient
			:quant (x7 / person
				:op 11)
			:ARG1-of (x8 / include-91))
		:polarity -
		:ARG1 (x15 / cancer
			:ARG1 (x13 / trace-02))
		:ARG2 (x19 / or
			:op1 (x18 / blood)
			:op4 (x21 / marrow
				:ARG1 (x20 / bone)))
		:ARG2 (x28 / amount
			:mod (x27 / small)
			:ARG1-of (x29 / remain-01))
		:ARG2 (x36 / decline-01
			:ARG1 (x39 / marrow
				:mod (x37 / further)
				:mod (x38 / bone))
			:ARG1 (x40 / monitor-01)))
	:ARG0 (x43 / person
		:name (n / name
			:op1 "Piro")))

# ::id 24
# ::snt His blood tests are normal, Dr. Piro added
(x9 / add-01
	:ARG1 (x5 / normal
		:domain (x3 / test-01
			:ARG1 (x2 / blood)))
	:ARG0 (x8 / person
		:name (n / name
			:op1 "Piro")))

# ::id 25
# ::snt None of the patients have had a relapse ; complete remission has lasted from seven to 46 months after treatment, according to the study
(x / xconcept
	:x (x9 / and
		:op1 (x6 / have-03
			:ARG2 (x4 / patient)
			:ARG1 (x8 / relapse-01))
		:op2 (x13 / last-01
			:ARG1 (x11 / remission
				:mod (x10 / complete))
			:ARG2 (x18 / temporal-quantity
				:unit (m / month)
				:quant 46)
			:time (x19 / after
				:op1 (x20 / treat-03))
			:ARG2 (x25 / study-01))))

# ::id 26
# ::snt " When you can make all the disease go away with a single infusion of therapy, you have a disease which may be able to be cured, " Dr. Piro said
(x33 / say-01
	:ARG1 (x19 / have-03
		:ARG0 (x3 / you
			:mod (x4 / possible
				:domain (x9 / go-01
					:ARG1 (x8 / disease
						:quant (x6 / all))
					:direction (x10 / away)
					:instrument (x14 / infusion
						:mod (x13 / single)
						:ARG1 (x16 / therapy)))))
		:ARG0 (x18 / you)
		:ARG1 (x21 / disease
			:mod (x25 / possible
				:mod (x23 / possible)
				:domain (x28 / cure-01))))
	:ARG0 (x32 / person
		:name (n / name
			:op1 "Piro")))

# ::id 27
# ::snt But because hairy-cell leukemia proliferates slowly, a relapse could occur long after treatment
(x1 / contrast-01
	:ARG2 (x2 / cause-01
		:ARG0 (x5 / proliferate-01
			:ARG0 (x4 / disease
				:name (n / name
					:op1 "leukemia")
				:mod (x3 / hairy-cell))
			:manner (x6 / slow)))
	:ARG2 (x9 / relapse-01)
	:ARG2 (x10 / possible
		:time (x12 / long)
		:time (x13 / after
			:op1 (x14 / treat-03))))

# ::id 28
# ::snt Longer follow-up is necessary to determine whether 2-CdA actually cures the disease
(x4 / necessary
	:null_edge (x6 / determine-01
		:ARG0 (x2 / follow-up
			:duration (x1 / long))
		:ARG1 (x10 / thing
			:ARG3-of (c / cure-01)
			:ARG0 (x8 / 2-cda)
			:mod (x9 / actual)
			:ARG1 (x12 / disease))))

# ::id 29
# ::snt The drug was first made about 10 years ago at Scripps by Dennis A. Carson, who studied severe combined immunodeficiency disease, made famous a few years ago by the Texas boy that lived in a bubble
(xap0 / before
	:ARG1 (x2 / drug)
	:quant (x8 / temporal-quantity
		:unit (y / year)
		:null_edge (x7 / null_tag))
	:location (x11 / organization
		:name (n / name
			:op1 "Scripps"))
	:ARG0 (x18 / study-01
		:ARG1 (x22 / disease
			:mod (x19 / severe)
			:mod (x20 / combine-01)
			:mod (x21 / immunodeficiency)
			:mod (x25 / famous
				:null_edge (x27 / few
					:op1 (x28 / temporal-quantity
						:unit (y1 / year)))
				:ARG0 (x33 / boy
					:mod (x32 / country
						:name (n1 / name
							:op1 "Texas"))
					:ARG0-of (x35 / live-01
						:manner (x38 / bubble)))))))

# ::id 30
# ::snt People with that disease lack an enzyme that processes deoxyadenosine, a chemical that, without the enzyme, builds up in infection-fighting white blood cells and kills them
(x5 / lack-01
	:ARG1 (x4 / disease
		:mod (x3 / that))
	:ARG1 (x7 / enzyme
		:ARG0-of (x9 / process-01
			:ARG1 (x10 / deoxyadenosine
				:mod (x13 / chemical
					:ARG0-of (x20 / build-01
						:manner (x18 / enzyme)
						:location (x26 / cell
							:ARG1-of (x23 / infection-fighting)
							:mod (x24 / white)
							:mod (x25 / blood))
						:ARG1 (x27 / and
							:op2 (x28 / kill-01))))))))

# ::id 31
# ::snt Since cancer patients have the enzyme, Scripps scientists developed a compound that mimics deoxyadenosine, but tricks the enzyme so it ca n't be processed
(x10 / develop-02
	:concession (x4 / have-03
		:ARG0 (x3 / patient
			:mod (x2 / cancer))
		:ARG1 (x6 / enzyme))
	:ARG0 (x9 / scientist
		:mod (x8 / organization
			:name (n / name
				:op1 "Scripps")))
	:ARG1 (x12 / compound-01
		:ARG0-of (x14 / mimic)
		:mod (x18 / trick
			:ARG1 (x20 / enzyme)
			:ARG1-of (x26 / process-01))))

# ::id 32
# ::snt The compound then kills the white blood cells, including those that are cancerous
(x4 / kill-01
	:ARG0 (x2 / compound-01)
	:time (x3 / then)
	:ARG1 (x8 / cell
		:null_edge (x6 / white)
		:mod (x7 / blood)
		:mod (x14 / cancerous)))

# ::id 33
# ::snt New, normal white cells are then generated in the bone marrow
(x8 / generate-01
	:ARG1 (x5 / cell
		:null_edge (x1 / null_tag)
		:mod (x3 / normal)
		:mod (x4 / white))
	:time (x7 / then)
	:ARG2 (x12 / marrow
		:ARG1 (x11 / bone)))

# ::id 34
# ::snt Because hairy-cell leukemia is rare, a 12-patient study " is considered a pretty good series, " says Sloan-Kettering's Dr. Berman
(x19 / say-01
	:ARG1 (x12 / consider-01
		:ARG1-of (x1 / cause-01
			:ARG0 (x5 / rare
				:domain (x3 / disease
					:name (n1 / name
						:op1 "leukemia")
					:mod (x2 / hairy-cell))))
		:ARG1 (x9 / study
			:mod (x8 / 12-patient))
		:ARG1 (x16 / series
			:mod (x15 / good
				:degree (x14 / pretty))))
	:ARG0 (x23 / person
		:name (n / name
			:op1 "Berman")
		:null_edge (x20 / sloan-kettering)))

# ::id 35
# ::snt " It's ironic that we have three active drugs for a disease that's fairly rare, but for some of the more common forms of leukemia, we do n't yet have good treatments .
(x19 / contrast-01
	:ARG1 (xap0 / contrast-01
		:ARG2 (x4 / irony
			:domain (x2 / it)
			:domain (x7 / have-03
				:ARG0 (x6 / we)
				:ARG1 (x10 / drug
					:quant 3
					:mod (x9 / active)
					:purpose (x13 / disease
						:mod (x17 / rare
							:degree (x16 / fair)))))
			:ARG1 (x36 / treat-03
				:beneficiary (x21 / some)
				:purpose (x28 / disease
					:name (n / name
						:op1 "leukemia")
					:mod (x26 / form
						:mod (x25 / common
							:degree (x24 / more))))
				:poss (x30 / we)
				:time (x33 / yet)
				:mod (x35 / good)))))

# ::id 36
# ::snt Dr. Piro said 2-CdA has also been used effectively in initial trials to treat more common cancers, including chronic lymphocytic leukemia, non-Hodgkins lymphoma and cutaneous T-cell lymphoma
(x3 / say-01
	:ARG0 (x2 / person
		:name (n / name
			:op1 "Piro"))
	:ARG1 (x8 / use-01
		:ARG1 (x4 / 2-cda)
		:mod (x6 / also)
		:manner (x9 / effective)
		:ARG2 (x12 / trial
			:mod (x11 / initial))
		:ARG2 (x14 / treat-01
			:ARG1 (x17 / cancer
				:mod (x16 / common
					:degree (x15 / more))
				:ARG2-of (x19 / include-91
					:ARG1 (x26 / and
						:op1 (x22 / disease
							:name (n1 / name
								:op1 "leukemia")
							:mod (x20 / chronic)
							:mod (x21 / lymphocytic)
							:mod (x24 / organization
								:name (n2 / name
									:op1 "non-Hodgkins")))
						:op2 (x29 / lymphoma
							:mod (x27 / cutaneous)
							:ARG1 (x28 / have-org-role-91
								:ARG1 (o / organization
									:name (n3 / name
										:op1 "T-cell"))))))))))

# ::id 37
# ::snt About 50 % to 60 % of patients -- most of whom had failed other treatments -- responded to the drug, some with complete remission, he said
(x29 / say-01
	:ARG1 (x18 / respond-01
		:ARG2 (x21 / drug
			:ARG1-of (x26 / remission
				:mod (x25 / complete)))
		:ARG2 (xap0 / percentage-entity
			:value 50
			:ARG2 (x8 / patient
				:ARG2-of (x11 / include-91
					:quant (x10 / most))
				:ARG1-of (x14 / fail-01
					:ARG1 (x16 / treat-03
						:mod (x15 / other))))
			:ARG0-of (xap1 / percentage-entity
				:value 60)))
	:ARG0 (x28 / he))

# ::id 38
# ::snt " Now, we will use -LCB- 2-CdA -RCB- as a first treatment to see if response and remission are higher, " he said
(x25 / say-01
	:ARG1 (x6 / use-01
		:time (x2 / now)
		:ARG0 (x4 / we)
		:ARG1 (x8 / 2-cda)
		:ARG2 (x13 / treat-03)
		:ARG2 (x15 / see-01
			:ARG1 (x18 / and
				:op1 (x17 / respond-01)
				:op2 (x19 / remission)
				:op2 (x21 / high))))
	:ARG0 (x24 / he))

# ::id 39
# ::snt Meanwhile, researchers at University of California at San Francisco are testing 2-CdA on AIDS-related lymphoma
(x12 / test-01
	:time (x1 / meanwhile)
	:ARG0 (x3 / person
		:ARG0-of (r / research-01)
		:location (x7 / state
			:name (n / name
				:op1 "California")
			:location (x9 / city
				:name (n1 / name
					:op1 "San"
					:op2 "Francisco"))))
	:ARG1 (x13 / 2-cda)
	:ARG1 (x16 / lymphoma
		:mod (x15 / aids-related)))

